Real-life Data of Constitutional Von Willebrand Disease in Western France

Nantes University Hospital922 enrolled

Overview

The objective of this observational study HOPSCOTcH-WILL II is to provide an accurate and detailed account of current Von Willebrand Disease (VWD) therapeutic management by collecting real-life data on hemorrhagic treated events in the 5 Western French Hemophilia Treatment Center. The HOPSCOTCH-WILL II study aims to describe therapeutic management of patients with VWD, following the provision of a recombinant drug in France; It will also permit to carry out a budget impact analysis to quantify the economic significance of this new era.

Study Type

OBSERVATIONAL

Enrollment

922

Conditions

Von Willebrand Diseases

Interventions

no interventionOTHER

no intervention

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Constitutional Von Willebrand Disease patient, of any severity, with or without Von Willebrand Factors inhibitors * Patient included in the research database BERHLINGO * Patient treated or not by desmopressin or Von Willebrand Factor/FVIII/by-passing agents available on the French market (at baseline) * Patient who agrees to participate in the HOPSCOTcH-Will II and followed in one of the 5 investigator centers Exclusion Criteria: \- Patients under guardianship

Locations (5)

CHU Angers

Angers, France

CHR de Brest

Brest, France

CH Le Mans

Le Mans, France

CHU de Nantes

Nantes, France

CHU Rennes

Rennes, France

Outcomes

Primary Outcomes

Observational study, description of the global therapeutic modalities required for severe treated hemorrhagic events in constitutional Von Willebrand Disease patients of any severity

Data collection for evaluation of Clotting factors quantities used by collection of treatments for severe hemorrhagic events

Time frame: 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.